Name

Bosutinib

Alternate Names

Bosulif
SKI 606
SKI-606

Abbreviations

BOS

Category

Chemotherapy

Subcategory

Tyrosine kinase inhibitor

NSC Number

None

Primary Site

CML

Histology

None

Remarks

9/26/2023 The FDA approved bosutinib (Bosulif) for pediatric patients 1 year of age and older with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) that is newly diagnosed (ND) or resistant or intolerant (R/I) to prior therapy.

12/19/2017: FDA granted accelerated approval to bosutinib for treatment of patients with newly diagnosed chronic-phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML).

9/4/2012: Bosulif received FDA approval as an Orphan Drug to treat CML

Coding

This drug should be coded
Glossary